CLDX - So did CLDX only enroll ~33 patients with high GPNMB expression? Slide 5 suggests that they knew CDX011 was more effective in those patients so why not enroll more than ~25% pf patients? ECYT made a similar mistake where they enrolled FR- patients in the randomized trial AND included them in the analysis of the primary endpoint.
Also was there any mention of patients who had even higher GPNMB expression in the conference call(higher cut off than 25)? Presumably the results would have been even better.
Market Data 
Markets 
AI
